vs
Ametek（AME）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
Ametek的季度营收约是Medpace Holdings, Inc.的2.8倍（$2.0B vs $708.5M）。Ametek净利率更高（19.9% vs 19.1%，领先0.9%）。Medpace Holdings, Inc.同比增速更快（32.0% vs 13.4%）。Ametek自由现金流更多（$527.3M vs $188.1M）。过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs 7.3%）
AMETEK Inc.是美国跨国综合企业，为全球知名的电子仪器及机电设备设计商与制造商，总部位于美国，在全球范围内设有超过150个运营站点，业务覆盖多个国家和地区，为各行业客户提供高性能的相关产品及配套解决方案。
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
AME vs MEDP — 直观对比
营收规模更大
AME
是对方的2.8倍
$708.5M
营收增速更快
MEDP
高出18.6%
13.4%
净利率更高
AME
高出0.9%
19.1%
自由现金流更多
AME
多$339.2M
$188.1M
两年增速更快
MEDP
近两年复合增速
7.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $2.0B | $708.5M |
| 净利润 | $398.6M | $135.1M |
| 毛利率 | 36.0% | — |
| 营业利润率 | 25.3% | 21.6% |
| 净利率 | 19.9% | 19.1% |
| 营收同比 | 13.4% | 32.0% |
| 净利润同比 | 2.9% | 15.5% |
| 每股收益（稀释后） | $1.73 | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMEMEDP
| Q4 25 | $2.0B | $708.5M | ||
| Q3 25 | $1.9B | $659.9M | ||
| Q2 25 | $1.8B | $603.3M | ||
| Q1 25 | $1.7B | $558.6M | ||
| Q4 24 | $1.8B | $536.6M | ||
| Q3 24 | $1.7B | $533.3M | ||
| Q2 24 | $1.7B | $528.1M | ||
| Q1 24 | $1.7B | $511.0M |
净利润AMEMEDP
| Q4 25 | $398.6M | $135.1M | ||
| Q3 25 | $371.4M | $111.1M | ||
| Q2 25 | $358.4M | $90.3M | ||
| Q1 25 | $351.8M | $114.6M | ||
| Q4 24 | $387.3M | $117.0M | ||
| Q3 24 | $340.2M | $96.4M | ||
| Q2 24 | $337.7M | $88.4M | ||
| Q1 24 | $310.9M | $102.6M |
毛利率AMEMEDP
| Q4 25 | 36.0% | — | ||
| Q3 25 | 36.3% | — | ||
| Q2 25 | 35.8% | — | ||
| Q1 25 | 36.1% | — | ||
| Q4 24 | 36.6% | — | ||
| Q3 24 | 36.0% | — | ||
| Q2 24 | 36.0% | — | ||
| Q1 24 | 34.1% | — |
营业利润率AMEMEDP
| Q4 25 | 25.3% | 21.6% | ||
| Q3 25 | 25.8% | 21.5% | ||
| Q2 25 | 26.0% | 20.9% | ||
| Q1 25 | 26.3% | 20.3% | ||
| Q4 24 | 26.6% | 23.4% | ||
| Q3 24 | 26.1% | 21.1% | ||
| Q2 24 | 25.8% | 19.9% | ||
| Q1 24 | 24.0% | 20.4% |
净利率AMEMEDP
| Q4 25 | 19.9% | 19.1% | ||
| Q3 25 | 19.6% | 16.8% | ||
| Q2 25 | 20.2% | 15.0% | ||
| Q1 25 | 20.3% | 20.5% | ||
| Q4 24 | 22.0% | 21.8% | ||
| Q3 24 | 19.9% | 18.1% | ||
| Q2 24 | 19.5% | 16.7% | ||
| Q1 24 | 17.9% | 20.1% |
每股收益（稀释后）AMEMEDP
| Q4 25 | $1.73 | $4.65 | ||
| Q3 25 | $1.60 | $3.86 | ||
| Q2 25 | $1.55 | $3.10 | ||
| Q1 25 | $1.52 | $3.67 | ||
| Q4 24 | $1.67 | $3.67 | ||
| Q3 24 | $1.47 | $3.01 | ||
| Q2 24 | $1.45 | $2.75 | ||
| Q1 24 | $1.34 | $3.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $458.0M | $497.0M |
| 总债务越低越好 | $2.3B | — |
| 股东权益账面价值 | $10.6B | $459.1M |
| 总资产 | $16.1B | $2.0B |
| 负债/权益比越低杠杆越低 | 0.21× | — |
8季度趋势，按日历期对齐
现金及短期投资AMEMEDP
| Q4 25 | $458.0M | $497.0M | ||
| Q3 25 | $439.2M | $285.4M | ||
| Q2 25 | $619.7M | $46.3M | ||
| Q1 25 | $399.0M | $441.4M | ||
| Q4 24 | $374.0M | $669.4M | ||
| Q3 24 | $396.3M | $656.9M | ||
| Q2 24 | $396.6M | $510.9M | ||
| Q1 24 | $373.8M | $407.0M |
总债务AMEMEDP
| Q4 25 | $2.3B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AMEMEDP
| Q4 25 | $10.6B | $459.1M | ||
| Q3 25 | $10.5B | $293.6M | ||
| Q2 25 | $10.4B | $172.4M | ||
| Q1 25 | $10.0B | $593.6M | ||
| Q4 24 | $9.7B | $825.5M | ||
| Q3 24 | $9.6B | $881.4M | ||
| Q2 24 | $9.3B | $763.6M | ||
| Q1 24 | $9.0B | $671.5M |
总资产AMEMEDP
| Q4 25 | $16.1B | $2.0B | ||
| Q3 25 | $16.2B | $1.8B | ||
| Q2 25 | $15.3B | $1.6B | ||
| Q1 25 | $14.9B | $1.9B | ||
| Q4 24 | $14.6B | $2.1B | ||
| Q3 24 | $14.8B | $2.1B | ||
| Q2 24 | $14.8B | $1.9B | ||
| Q1 24 | $14.9B | $1.8B |
负债/权益比AMEMEDP
| Q4 25 | 0.21× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.22× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $584.3M | $192.7M |
| 自由现金流经营现金流 - 资本支出 | $527.3M | $188.1M |
| 自由现金流率自由现金流/营收 | 26.4% | 26.6% |
| 资本支出强度资本支出/营收 | 2.9% | 0.6% |
| 现金转化率经营现金流/净利润 | 1.47× | 1.43× |
| 过去12个月自由现金流最近4个季度 | $1.7B | $681.9M |
8季度趋势，按日历期对齐
经营现金流AMEMEDP
| Q4 25 | $584.3M | $192.7M | ||
| Q3 25 | $440.9M | $246.2M | ||
| Q2 25 | $359.1M | $148.5M | ||
| Q1 25 | $417.5M | $125.8M | ||
| Q4 24 | $550.0M | $190.7M | ||
| Q3 24 | $487.2M | $149.1M | ||
| Q2 24 | $381.4M | $116.4M | ||
| Q1 24 | $410.2M | $152.7M |
自由现金流AMEMEDP
| Q4 25 | $527.3M | $188.1M | ||
| Q3 25 | $420.0M | $235.5M | ||
| Q2 25 | $329.8M | $142.4M | ||
| Q1 25 | $394.5M | $115.8M | ||
| Q4 24 | $498.3M | $183.0M | ||
| Q3 24 | $460.9M | $138.5M | ||
| Q2 24 | $360.0M | $103.5M | ||
| Q1 24 | $382.6M | $147.2M |
自由现金流率AMEMEDP
| Q4 25 | 26.4% | 26.6% | ||
| Q3 25 | 22.2% | 35.7% | ||
| Q2 25 | 18.5% | 23.6% | ||
| Q1 25 | 22.8% | 20.7% | ||
| Q4 24 | 28.3% | 34.1% | ||
| Q3 24 | 27.0% | 26.0% | ||
| Q2 24 | 20.8% | 19.6% | ||
| Q1 24 | 22.0% | 28.8% |
资本支出强度AMEMEDP
| Q4 25 | 2.9% | 0.6% | ||
| Q3 25 | 1.1% | 1.6% | ||
| Q2 25 | 1.6% | 1.0% | ||
| Q1 25 | 1.3% | 1.8% | ||
| Q4 24 | 2.9% | 1.4% | ||
| Q3 24 | 1.5% | 2.0% | ||
| Q2 24 | 1.2% | 2.4% | ||
| Q1 24 | 1.6% | 1.1% |
现金转化率AMEMEDP
| Q4 25 | 1.47× | 1.43× | ||
| Q3 25 | 1.19× | 2.22× | ||
| Q2 25 | 1.00× | 1.65× | ||
| Q1 25 | 1.19× | 1.10× | ||
| Q4 24 | 1.42× | 1.63× | ||
| Q3 24 | 1.43× | 1.55× | ||
| Q2 24 | 1.13× | 1.32× | ||
| Q1 24 | 1.32× | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AME
| Transferred At Point In Time | $1.1B | 54% |
| Electronic Instruments Group | $620.1M | 31% |
| Transferred Over Time | $294.6M | 15% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
